Your session is about to expire
← Back to Search
Vagus Nerve Stimulation for Epilepsy
Study Summary
This trialwill test how well stimulating the vagus nerve with a device can activate the nerve and reduce side effects. It'll use adult epilepsy patients already having surgery to implant or replace the device.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am an adult with epilepsy getting a VNS device implanted or replaced.My neurological condition is stable, except for epilepsy.
- Group 1: Investigational Stimulation Parameters
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Do applicants for this trial need to meet certain age criteria?
"This research is open for patients of legal age, that being over 18 and under 65."
Are there still opportunities to become involved in this research endeavor?
"According to the clinicaltrials.gov records, this particular medical trial is not currently enrolling patients. The study was initially posted on December 1st 2022 and its most recent update occurred in November 4th 2022. Unfortunatly, participants are being sought for other trials active at present; a total of 239 studies need volunteers as we speak."
What are the criteria for eligibility to participate in this trial?
"Those that wish to be considered for this trial must present with aura and adhere to an age range of 18-65 years old. Altogether, the study is looking to enrol eighteen individuals."
Share this study with friends
Copy Link
Messenger